Early Combination of Albumin With Crystalloid Administration Might Reduce Mortality in Patients With Cardiogenic Shock: An Over 10-Year Intensive Care Survey

Zhi-ye Zou1†, Bin Wang2†, Wen-jun Peng3, Zhi-peng Zhou1, Jia-jia Huang1,4, Zhen-jia Yang1,4, Jing-jing Zhang1,4, Ying-yi Luan5, Biao Cheng6* and Ming Wu1,4,7,8*

1 Department of Critical Care Medicine and Hospital Infection Prevention and Control, Shenzhen Second People’s Hospital & First Affiliated Hospital of Shenzhen University, Shenzhen, China, 2 Department of Ultrasound, Longgang Central Hospital of Shenzhen, Shenzhen, China, 3 Department of Cardiovascular, Longgang Central Hospital of Shenzhen, Shenzhen, China, 4 Department of Cardiology, Longgang Central Hospital of Shenzhen, Shenzhen, China, 5 Department of Ultrasound, Daxing General Hospital, Beijing, China, 6 Department of Plastic Surgery, General Hospital of Southern Theatre Command of People’s Liberation Army, Guangzhou, China, 7 Department of Obstetrics and Gynecology, Capital Medical University, Beijing, China, 8 Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

*Correspondence:
Biao Cheng
chengbiaocheng@163.com
Ming Wu
boshiyy@126.com

† These authors have contributed equally to this work

Background: In updated international guidelines, combined albumin resuscitation is recommended for septic shock patients who receive large volumes of crystalloids, but minimal data exist on albumin use and the optimal timing in those with cardiogenic shock (CS). The objective of this study was to evaluate the relationship between resuscitation with a combination of albumin within 24 h and 30-day mortality in CS patients.

Methods: We screened patients with CS from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Multivariable Cox proportional hazards models and propensity score matching (PSM) were employed to explore associations between combined albumin resuscitation within 24 h and 30-day mortality in CS. Models adjusted for CS considered potential confounders. E-value analysis suggested for unmeasured confounding.

Results: We categorized 1,332 and 254 patients into crystalloid-only and early albumin combination groups, respectively. Patients who received the albumin combination had decreased 30-day and 60-day mortality (21.7 vs. 32.4% and 25.2 vs. 34.2%, respectively, \( P < 0.001 \)), and the results were robust after PSM (21.3 vs. 44.7% and 24.9 vs. 47.0%, respectively, \( P < 0.001 \)) and following E-value. Stratified analysis showed that only \( \geq 60 \) years old patients benefited from administration early albumin. In the early albumin combination group, the hazard ratios (HRs) of different adjusted covariates remained significant (HRs of 0.45–0.64, \( P < 0.05 \)). Subgroup analysis showed that resuscitation with combination albumin was significantly associated with reduced 30-day mortality in patients with maximum sequential organ failure assessment score \( \geq 10 \),
with acute myocardial infarction, without an Impella or intra-aortic balloon pump, and with or without furosemide and mechanical ventilation (HRs of 0.49, 0.58, 0.65, 0.40, 0.65 and 0.48, respectively; \( P < 0.001 \)).

Conclusion: This study found, compared with those given crystalloid-only, resuscitation with combination albumin within 24 h is associated with lower 30-day mortality of CS patients aged \( \geq 60 \). The results should be conducted to further assess in randomized controlled trials.

Keywords: cardiogenic shock, fluid therapy, albumins, mortality, early combination

INTRODUCTION

Cardiogenic shock (CS) is a clinical syndrome characterized by significantly reduced cardiac output, whereby an extreme decline in cardiac function may result in severe acute circulatory failure (1). Despite significant advances in CS therapy in recent years, namely, with the gradual application of the intra-aortic balloon pump (IABP), percutaneous coronary intervention (PCI), the Impella pump and extracorporeal membrane oxygenation (ECMO), the clinical mortality of CS still exceeds 40% (2).

Prompt and effective treatment is crucial for patients with CS. Aetiological treatment, timely use of vasoactive drugs, and mechanical assistance have been recognized and confirmed by clinical studies (3, 4). In addition, intravenous infusion for patients with CS is primarily based on pathophysiological considerations. According to current guidelines, fluid resuscitation should be considered as first-line treatment unless there are clear signs of fluid overload (4). However, the specific fluid type of resuscitation is not specified in the latest guidelines. Furthermore, there is limited literature on the type of fluid required for resuscitation in patients with CS.

Many previous studies have found no association with lower mortality in the intensive care unit (ICU) among patients with severe sepsis or septic shock receiving colloid therapy compared with crystalloids (5, 6). Nevertheless, a recent retrospective study using propensity score matching (PSM) to adjust confounding and restricted mean survival time (RMST) analysis showed that early combined use of albumin might improve the survival rate of patients with sepsis (7), and the heterogeneity of septic shock might be responsible for disparate findings. The updated international guidelines suggest using albumin in adult patients who receive large volumes of crystalloids for septic shock (8). Albumin is the most abundant plasma protein and has many biological functions, including binding to endo- and exogenous substances (9), antithrombotic effects (10) and maintenance of colloidal osmotic pressure (11). Based on different clinical types of shock, the pathophysiological characteristics of patients also differ, and it remains unclear whether combined albumin resuscitation can improve the prognosis of CS patients. Therefore, to evaluate the effectiveness of albumin for patients with CS, we used the Medical Information Mart for Intensive Care IV (MIMIC-IV) database to assess whether resuscitation with combination albumin within 24 h after CS onset was associated with lower 30-day mortality.

MATERIALS AND METHODS

Study Design, Data Source and Participants

We performed a retrospective cohort study using MIMIC-IV version 1.0 (12) data (https://physionet.org/content/mimiciv/1.0/), which are sourced from two inpatient database systems: the customized hospital Electronic Medical Record System (EHR) and the clinical information system of the intensive care unit (ICU). MIMIC-IV contains 256,878 patients from 2008 to 2019 and includes demographic, vital sign, laboratory test, and drug data, among others. The database is an upgraded version of MIMIC-III with high-quality critical medical data. Author ZOU (Certification number 35951237) has completed the Collaborative Institutional Training Initiative examination and can access the MIMIC-IV database.

The inclusion criteria were in accordance with ICD-9 (785.51 and 998.01) and ICD-10 (R57.0 and T81.11XA) diagnosis codes and patients who were resuscitated within 24 h after CS onset. The exclusion criteria were as follows: age \( < 18 \) years old; data from multiple intensive care unit (ICU) admission other than the first admission; secondary diagnosis of liver disease, solid tumor, or other cancer on admission (ICD-9 or ICD-10); ICU stay \( < 24 \) h; albumin preceded crystalloid; combined albumin \( > 24 \) h; no crystalloid given. For patients admitted to the ICU multiple times, we only included data from the first admission.

Research Procedures and Definitions

We categorized patients into a crystalloid-only group and an early combination group (crystalloid combined with albumin in the first 24 h); we extracted data using a structure query language (SQL) with Navicat Premium tools (version 12.1.12). The following data were recorded: age, sex, ethnicity, insurance, weight, probable etiologies, history of diseases, Charlson comorbidity index (CCI), vital signs on the first day, the first day of maximum Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology Score II (SAPS) score, laboratory findings, central venous pressure (CVP), in-hospital management and medication, stage of acute kidney injury (AKI) (13) and fluid type during ICU stay. In-hospital management included percutaneous coronary intervention (PCI), intra-aortic balloon pump (IABP), Impella pump, mechanical ventilation, and renal replacement therapy (RRT). Probable etiologies included acute myocardial infarction (AMI) (14) and acute heart failure (AHF) (15). Dopamine, norepinephrine, and their
total usage time were collected as in-hospital medication data. In this study, crystalloids included both normal saline and lactated Ringer’s (LR) solution; albumin included 5% and 25% human serum albumin (HSA). The main outcome was mortality including 30-day mortality and 60-day mortality.

**Statistical Analysis**
Data are presented as the mean ± standard deviation (mean ± SD), median and interquartile interval (median, IQR), or percentage (n%), as appropriate. Comparisons between the crystalloid-only group and early combination group were performed using Student’s t test, the Mann–Whitney test, and the χ² test, as appropriate. Risk factors affecting clinical outcomes, including etiology (AMI), in-hospital management (IABP or IMPELLA) and medication (furosemide), and disease severity (SOFA), were examined for an association with 30-day mortality using a Cox proportional hazards model. An extended Cox model was applied to adjust for covariates that might affect outcomes. We also explored the potential for unmeasured confounding between early resuscitation with albumin and 30-day mortality by calculating E-values (16). The E-value quantifies the required magnitude of an unmeasured confounder that might negate the observed association between combined albumin and 30-day mortality.

Propensity score matching (PSM) was selected to balance confounding factors. Variables including age, sex, ethnic group, insurance condition, weight, probable etiology, history of the disease, CCI, vital signs on the first day, the first day of maximum SOFA and SAPS scores, and in-hospital management and medication were chosen to generate the PS based on clinical significance and previous literature. We used a multivariable logistic regression model. A one-to-one nearest neighbor matching algorithm was applied using a caliper width of 0.2. After PSM, we used the standardized mean difference (SMD) and P-value to judge the balance of essential characteristics between the groups. When the SMD of a variable is larger than 0.1, it can be considered an imbalance between groups (17). Finally, 253 patients in each group were well matched, and their data were extracted for further analyses. We also performed analysis of interaction between age and early albumin administration with a Cox proportional hazards model and performed PSM analysis for CS patients with no albumin deficiency on day1. Risk factors for 30-day mortality were also evaluated, and the analysis was conducted in the population after PSM. Survival analysis for patients with and without albumin treatment was performed using Kaplan–Meier (K–M) analysis and log-rank tests before and after PSM.

Subgroup and interaction analyses were carried out to determine whether albumin administration and 30-day mortality differ across various subgroups classified by SOFA, AMI, IABP, furosemide, and mechanical ventilation. Subgroup analysis also used a Cox model adjusted for all variables included in patient baseline information. Average values were used to replace the missing values of some variables. Multiple imputations were used for missing values under the assumption of missing at random (18). Two-tailed P values <0.05 were considered to indicate statistical significance. All statistical analyses were performed using Stata 15.1 (StataCorp, College Station, TX, USA), Empower (R; www.empowerstats.com; X&Y Solutions Inc.) and R 4.0.1 software for Windows.

**RESULTS**

**Baseline Characteristics**
Data for 2,551 patients with CS were evaluated, and 1,586 patients were included in the study (Figure 1). For fluid resuscitation
TABLE 1 | Baseline characteristics between the two groups before and after propensity score matching (PSM).

| Variables                      | Propensity score matching | Before (total population) | Crystalloids only (n = 1,332) | Early combination (n = 254) | P value | After (Crystalloids only n = 253) | Early combination (n = 253) | P value | SMD |
|--------------------------------|--------------------------|---------------------------|------------------------------|-----------------------------|---------|--------------------------------|------------------------------|---------|-----|
| Age (year), median (IQR)       |                          | 72.2 (61.9, 81.1)         | 72.3 (61.9, 81.9)            | 71.4 (61.8, 78.2)           | 0.063   | 71.07 (59.47, 81.82)            | 71.51 (62.01, 78.18)         | 0.65    | 0.30|
| Male, n (%)                    |                          | 954 (60.2)                | 793 (59.5)                   | 161 (63.4)                  | 0.25    | 159 (62.8)                     | 160 (63.2)                   | 0.93    | 0.03|
| White, n (%)                   |                          | 851 (63.7)                | 715 (53.7)                   | 136 (53.5)                  | 0.24    | 131 (51.8)                     | 136 (63.8)                   | 0.64    | 0.04|
| Diagnosis, n (%)               |                          | 781 (49.2)                | 689 (51.7)                   | 92 (36.2)                   | <0.001  | 92 (36.4)                      | 92 (36.4)                    | 1.00    | <0.001|
| History of disease, n (%)      |                          | 1,232 (77.7)              | 1,016 (76.3)                 | 216 (85.0)                  | 0.002   | 208 (82.2)                     | 215 (85.0)                   | 0.40    | 0.075|
| Hypertension                   |                          | 642 (40.5)                | 544 (40.8)                   | 98 (38.6)                   | 0.50    | 92 (36.4)                      | 96 (38.7)                    | 0.58    | 0.049|
| Chronic pulmonary disease      |                          | 510 (32.2)                | 432 (32.4)                   | 78 (30.7)                   | 0.59    | 85 (33.6)                      | 78 (30.8)                    | 0.51    | 0.059|
| CKD                            |                          | 655 (41.3)                | 566 (42.5)                   | 89 (35.0)                   | 0.027   | 95 (37.5)                      | 89 (35.2)                    | 0.58    | 0.049|
| Stroke                         |                          | 193 (12.2)                | 152 (11.4)                   | 41 (16.1)                   | 0.035   | 42 (16.6)                      | 40 (15.8)                    | 0.81    | 0.021|
| Vital signs at 1st day, median (IQR) |                  | 81.0 (72.0, 88.0)         | 81.0 (72.0, 89.0)            | 80.0 (70.0, 85.5)           | 0.004   | 79.0 (70.0, 86.0)              | 80.0 (70.0, 85.0)            | 0.62    | 0.024|
| Scoring system, mean (SD)      |                          | 6.9 (2.5)                 | 6.9 (2.5)                    | 6.5 (2.4)                   | 0.009   | 6.40 (2.64)                    | 6.50 (2.39)                  | 0.66    | 0.039|
| Maximum SOFA at 1st day        |                          | 8.6 (4.1)                 | 8.2 (4.1)                    | 10.4 (3.5)                  | <0.001  | 10.6 (4.0)                     | 10.4 (3.4)                   | 0.52    | 0.057|
| Maximum SAPS II at 1st day     |                          | 45.2 (14.9)               | 44.7 (15.3)                  | 47.5 (12.7)                 | 0.006   | 48.6 (16.5)                    | 47.5 (12.8)                  | 0.41    | 0.073|
| Laboratory findings            |                          | 3.1 (0.6)                 | 3.3 (0.6)                    | 2.7 (0.8)                   | <0.001  | 2.97 (0.57)                    | 2.71 (0.78)                  | 0.11    | NA   |
| Minimum albumin at 1st day (g/dl), mean (SD) |   | 22.0 (20.0, 29.0)         | 21.0 (20.0, 30.0)            | 23.0 (20.0, 27.0)           | 0.016   | 21.0 (20.0, 28.0)              | 23.0 (20.0, 27.0)            | 0.12    | NA   |
| In-hospital medication, n (%)  |                          | 399 (25.2)                | 353 (26.5)                   | 46 (18.1)                   | 0.005   | 44 (17.4)                      | 46 (18.2)                    | 0.82    | 0.021|
| IAP                           |                          | 93 (5.9)                  | 84 (6.3)                     | 9 (3.5)                     | 0.086   | 11 (4.3)                       | 9 (3.6)                      | 0.65    | 0.041|
| IMPella                        |                          | 71 (4.5)                  | 58 (4.4)                     | 13 (5.1)                    | 0.59    | 12 (4.7)                       | 13 (5.1)                     | 0.84    | 0.018|
| In-hospital medication         |                          | 802 (50.6)                | 723 (54.3)                   | 79 (31.1)                   | <0.001  | 72 (28.5)                      | 79 (31.2)                    | 0.50    | 0.060|
| Dopamine at 1st day, n (%)     |                          | 316 (19.9)                | 303 (22.7)                   | 13 (5.1)                    | <0.001  | 12 (4.7)                       | 13 (5.1)                     | 0.84    | 0.018|
| Duration of dopamine (h), median (IQR) |     | 19.0 (4.0, 50.0)          | 19.0 (5.0, 50.0)             | 13.0 (3.5, 49.0)            | 0.66    | 19.0 (7.0, 34.0)               | 13.0 (3.5, 49.0)             | 0.81    | NA   |
| Norepinephrine at 1st day, n (%) |                      | 841 (53.0)                | 658 (49.4)                   | 183 (72.0)                  | <0.001  | 187 (73.9)                     | 182 (71.9)                   | 0.62    | 0.044|
| Duration of norepinephrine (h), median (IQR) | | 38.5 (16.0, 76.0)        | 37.0 (14.0, 74.0)            | 46.0 (22.0, 95.0)           | 0.004   | 45.0 (18.0, 77.0)              | 45.5 (22.0, 93.0)            | 0.26    | NA   |

IQR, interquartile range; AMI, acute myocardial infarction; AHF, acute heart failure; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; CCI, charlson comorbidity index; SOFA, sequential organ failure assessment; SAPS II, Simplified acute physiology score II; CVP, central venous pressure; PCI, percutaneous coronary intervention; IABP, intra-aortic balloon pump; NA, not applicable.
### TABLE 2 | Association between early albumin combination and outcomes in cardiogenic shock patients before and after PSM.

| Clinical outcomes                        | Crystalloids only | Early combination | Crystalloids only | Early combination | ARR (95%CI) | P-Value | ARR (95%CI) | P-Value |
|-----------------------------------------|-------------------|-------------------|-------------------|-------------------|-------------|---------|-------------|---------|
|                                          | Pre-matched cohort |                  | Post-matched cohort |                  |             |         |             |         |
|                                          | n = 1,332        | n = 254           | n = 253            | n = 253           |             |         |             |         |
| Minimum albumin at 2nd day (g/dl), mean (SD) | 3.0 (0.5)        | 3.0 (0.6)         | NA                | 2.8 (0.5)        | 3.0 (0.6)   | NA      | 2.8 (0.5)   | 3.0 (0.6) | 0.019 |
| Maximum CVP at 2nd day (mmHg), median (IQR) | 20.0 (19.0, 26.0) | 24.0 (20.0, 29.0) | NA                | 20.0 (18.0, 25.0) | 24.0 (20.0, 29.5) | NA      | <0.001      |         |
| Urine output (ml/1st 24 h), median (IQR) | 1,553.5 (775.0, 2,830.0) | 1,280.0 (704.5, 2,025.0) | NA                | 1,107.0 (400.0, 2,320.0) | 1,285.0 (710.0, 2,040.0) | NA      | 0.18        | <0.001   |
| Volume of crystalloid (ml/1st 24 h), median (IQR) | 2,050.0 (843.9, 4,011.7) | 4,409.2 (2,621.7, 6,682.5) | NA                | 3,626.6 (1,790.0, 5,643.1) | 4,458.5 (2,621.7, 6,682.5) | NA      | <0.001      |         |
| ICU LOS (days), mean (SD)                | 5.92 (5.34)      | 10.61 (11.34)     | NA                | 5.96 (6.31)      | 10.61 (11.36) | NA      | <0.001      |         |
| Hospital LOS (days), mean (SD)           | 11.5 (9.4)       | 17.7 (17.4)       | NA                | 10.05 (8.52)     | 17.72 (17.42) | NA      | <0.001      |         |
| AKI, n (%)                               | 910 (68.3)       | 196 (77.2)        | 8.85 (3.11, 14.58) | 0.005 | 177 (70.0) | 195 (77.1) | 7.11 (0.55, 14.78) | 0.070 |
| AKI stage 3, n (%)                        | 247 (18.5)       | 51 (20.1)         | 1.54 (3.82, 6.89) | 0.57 | 54 (21.3) | 51 (20.2) | 1.19 (5.88, 8.26) | 0.74 |
| RRT at 1st day, n (%)                     | 85 (6.4)         | 12 (4.7)          | 1.66 (−1.26, 4.58) | 0.31 | 26 (10.3) | 11 (4.3) | 5.93 (1.42, 10.44) | 0.010 |
| Mechanical ventilation at 1st day, n (%)  | 761 (57.1)       | 243 (95.7)        | −38.54 (−42.19, −34.89) | <0.001 | 168 (65.6) | 228 (90.1) | −24.51 (−31.42, −17.59) | <0.001 |
| 30-day mortality, n (%)                   | 431 (32.4)       | 55 (21.7)         | 10.70 (5.05, 16.36) | <0.001 | 113 (44.7) | 54 (21.3) | 23.32 (15.38, 31.26) | <0.001 |
| 60-day mortality, n (%)                   | 455 (34.2)       | 64 (25.2)         | 8.96 (3.05, 14.88) | 0.005 | 119 (47.0) | 63 (24.9) | 22.13 (14.0, 30.27) | <0.001 |

ARR, absolute risk reduction; CI, Confidence interval; CVP, central venous pressure; ICU, intensive care unit; LOS, length of stay; AKI, acute kidney injury; RRT, renal replacement therapy; NA, not applicable.
TABLE 3 | Analysis of interaction between age and early albumin administration.

| Crystalloids only | N | Crude HR (95% CI) | P-Value | Adjusted HR* (95% CI) | P-Value |
|-------------------|---|------------------|--------|----------------------|--------|
| Age < 50          | 126 | 1 (reference)    |        | 1 (reference)        |        |
| 50 ≤ Age < 60     | 155 | 1.10 (0.65, 1.85) | 0.734  | 1.04 (0.61, 1.79)    | 0.873  |
| 60 ≤ Age < 70     | 303 | 1.39 (0.88, 2.19) | 0.160  | 0.95 (0.58, 1.56)    | 0.850  |
| 70 ≤ Age < 80     | 356 | 2.18 (1.41, 3.37) | <0.001 | 1.24 (0.76, 2.05)    | 0.391  |
| 80 ≤ Age          | 392 | 2.37 (1.54, 3.64) | <0.001 | 1.24 (0.75, 2.04)    | 0.397  |
| Early combination |     |                  |        |                      |        |
| Age < 50          | 16  | 2.32 (0.95, 5.68) | 0.065  | 1.61 (0.65, 3.96)    | 0.301  |
| 50 ≤ Age < 60     | 39  | 0.41 (0.13, 1.34) | 0.140  | 0.26 (0.11, 1.17)    | 0.090  |
| 60 ≤ Age < 70     | 57  | 0.36 (0.12, 1.04) | 0.060  | 0.33 (0.11, 0.97)    | 0.044  |
| 70 ≤ Age < 80     | 91  | 0.22 (0.08, 0.61) | 0.004  | 0.22 (0.08, 0.62)    | 0.004  |
| 80 ≤ Age          | 51  | 0.14 (0.04, 0.43) | 0.001  | 0.12 (0.04, 0.40)    | <0.001 |

*The analysis of interaction effects used a Cox model adjusted for all variables included in patient baseline information.
†Stratification and interaction effects were performed for age.

in the first 24 h, 1,332 patients were given crystalloid only, whereas 254 patients were treated with crystalloid combined with albumin. The missing values of variables were shown in Supplementary Table 1.

In total, 1,586 patients with CS were included in this study (Table 1). The median (IQR) age was 72.2 (61.9, 81.1) years, 60.2% were male, 64.5% were white, and 49.2% had AMI. The crystalloid-only group had significantly higher AMI (51.7 vs. 36.2% P < 0.001), AHF, PCI, furosemide, dopamine, urine output, minimum SBP, and albumin (3.3 vs. 2.7g/dl, P < 0.001) on the first day than that in the early combination group. Compared to the crystalloid-only group, patients with higher SAPS II and SOFA scores were likelier to be given combined albumin in the first 24 h.

Outcomes

In PSM, 253 pairs of patients were matched by a 1:1 matching algorithm (Table 1 and Supplementary Figure 1). There was no significant difference between the two groups after PSM, and all SMDs were <0.01.

Patients who received the albumin combination had decreased 30-day mortality and 60-day mortality (21.7 vs. 32.4% and 25.2 vs. 34.2%, respectively, P < 0.001), and the results were robust after PSM (21.3 vs. 44.7% and 24.9 vs. 47.0%, respectively, P < 0.001; Table 2). The length of stay in ICU (10.61 vs. 5.96 days; P < 0.001) and hospital (10.61 vs. 5.96 days; P < 0.001) were significantly longer in the early combination group than in the crystalloids group. In the combination group, the percentage of received mechanical ventilation (95.7 vs. 57.1% P < 0.001) was significantly higher than in the crystalloids group. Compared with Age <50 years in the crystalloid-only group, the results showed that only 60 years old patients benefited from early albumin administration (Table 3). In extended multivariable Cox models, we found that the hazard ratio (HR) for different adjusted covariates was continuously significant in the early combination group (HR range 0.45–0.64, P < 0.05 for six models; Table 4). In Risk factors analysis showed early combination treatment remained a protective factor for 30-day mortality after PSM (HR 0.390, 95% CI 0.282–0.539; Supplementary Table 2). The primary findings were robust unless an unmeasured confounder existed regarding a lower relative risk of 30-day mortality, with an HR higher than 3.22 with E-value (Supplementary Text, Sensitivity Analysis Section).

As the albumin values for 59.33% (941/1,586) patients on day1, the results showed that there was no statistical difference between survivors and non-survivors (P = 0.072) between survivors and non-survivors in early albumin combination group (Supplementary Table 3). However, in CS patients aged ≥60 years with no albumin deficiency on day1, compared with the crystalloid-only group, we found early albumin combination was associated with reduced

TABLE 4 | Association between early albumin use and 30-day mortality using an extended model approach.

| Hazard ratio | 95% confidence interval | P-Value |
|--------------|-------------------------|--------|
| Model 1      | 0.62                    | 0.46–0.82 | 0.001 |
| Model 2      | 0.62                    | 0.47–0.83 | 0.001 |
| Model 3      | 0.64                    | 0.48–0.86 | 0.003 |
| Model 4      | 0.54                    | 0.39–0.72 | <0.001 |
| Model 5      | 0.47                    | 0.35–0.64 | <0.001 |
| Model 6      | 0.45                    | 0.33–0.62 | <0.001 |

Adjusted covariates: Model 1 = early albumin use. Model 2 = Model 1 + (History of disease including hypertension, diabetes, chronic pulmonary disease, CKD and stroke). Model 3 = Model 2 + (age gender ethnicity insurance weight). Model 4 = Model 3 + (probable etiology including AMI and AHF). Model 5 = Model 4 + (Scoring system including CCI, SOFA and SAPS II). Model 6 = Model 5 + (In-hospital management and medication including PCI, IABP, IMPELLA and Furosemide at 1st day).
30-day mortality (54 vs. 33%, \( P = 0.035 \)) and 60-day mortality (57 vs. 35%, \( P = 0.036 \); Supplementary Table 4).

Subgroup analysis was performed for AMI, maximum SOFA, IMPPELLA or IABP, furosemide, and mechanical ventilation (Figure 2). Early combination treatment was significantly associated with reduced 30-day mortality in the AMI subgroup (adjusted HR 0.58, 95% CI 0.35–0.96) but not in the non-AMI subgroup. The association between early combination treatment and 30-day mortality remained significant in other subgroups such as maximum SOFA ≥ 10, without IMPPELLA or IABP, and with or without furosemide and mechanical ventilation. Nonetheless, the association was not significant in IMPPELLA or IABP and maximum SOFA < 10 subgroups. Patients with AMI (HR = 0.58) showed a 42% reduction in 30-day mortality risk in the early albumin group than the crystal-only group. Patients without AMI (HR = 0.73) showed that the risk of death at 30 days was 27% lower in the early albumin group than in the crystal-only group. In the last column, \( P \) for interaction was 0.450, indicating that there was no significant difference in the relationship between albumin treatment and death between patients with and without AMI. That is to say, the previous differences of 0.58 and 0.73 in HR were not significant, and the relationship between albumin treatment and death at 30 days could not be considered to be different in patients with and without AMI. Other parameters like scoring system, IMPPELLA or IABP, furosemide, and mechanical ventilation are interpreted similarly to AMI.

### DISCUSSION

This study demonstrates that in CS, resuscitation with combination albumin within 24 h is associated with decreased 30-day and 60-day mortality (21.7 vs. 32.4% and 25.2 vs. 34.2%, respectively), prolonging the length of stay in the ICU (10.61 vs. 5.96 days) and increasing the incidence of mechanical ventilation (90.1 vs. 65.6%). Additionally, this result is stable in PSM analysis after adjusting for covariates. Results for subgroups of maximum SOFA ≥ 10, with AMI, without IMPPELLA or IABP, and with or without furosemide and mechanical ventilation were robust. However, the association is not significant in maximum SOFA < 10, IMPPELLA or IABP, and non-AMI subgroups. Our results suggest that early albumin combination therapy has a viable beneficial effect in patients aged ≥ 60 years with CS, which has not been previously reported.

There is still great controversy about the use of albumin for resuscitation in shock. Hill et al. (19) and Martin et al. (20) found that albumin administration increased the risk of pulmonary edema. Compared with crystalloids, most studies have shown that albumin has no effect on the outcome in critically ill patients (5, 21) and has no effect on pulmonary edema (22), and many studies have been carried out to further investigate the therapeutic effect of albumin. Indeed, comparisons of albumin and crystals have been studied in critically ill patients (23), sepsis (7), septic shock (24), non-cardiac surgery (21), hemorrhagic shock (25), and stroke (20). Nevertheless, some studies have shown that albumin can help to improve outcomes (24) and reduce multiple organ failure (26). In critically ill patients who need large-volume resuscitation (> 60 ml/kg within 24 h), 5% albumin was associated with reduced mortality and major adverse kidney events at 30, 90, and 365 days (27). Therefore, due to the heterogeneity of shock patients, albumin use in appropriate patients may improve outcomes.

Based on its pathophysiological characteristics, clinical shock can be divided into distributed shock, hypovolemic shock, obstructive shock, and cardiogenic shock. The latest sepsis guidelines recommend the use of albumin for patients undergoing massive crystalloid resuscitation, but there is no recommendation for CS. The causes of CS may be insufficient effective circulation due to coronary artery stenosis, myocarditis,
dystonia or dysfunction of the conduction bundle and peripheral blood vessels. Proper fluid resuscitation is an important approach for correcting insufficient circulation, but due to the high osmotic pressure of albumin, there may be subsequent fluid overload and pulmonary edema. Thus, rapid albumin infusion has become a relative contraindication of CS in primary health care without sufficient ability to monitor pulmonary oedema. Most guidelines, including in Europe (4, 15), the United States (1, 2), and France (28), indicate that in the absence of pulmonary edema, hypovolemic CS patients require resuscitation therapy, but most guidelines do not make specific recommendations with regard to the type of fluid. The 2016 ESC guidelines (15) recommend the use of normal saline or sodium lactate Ringer’s solution (>200 ml/15–30 min), but do not list evidence. Tewelde et al. (1) pointed out that crystal fluid for rescue treatment is recommended, similar to septic shock. However, there are significant differences in etiology and pathology between the two types of shock, and it is necessary to determine whether albumin can be used for fluid resuscitation of CS.
The main indication of albumin is hypoproteinaemia (albumin level below 3.0 g/dl). Hypoproteinaemia has been shown to be closely related not only to the mortality of patients with trauma (29) and other severe cases (30) but also to acute myocardial infarction (31) and acute or chronic heart failure (32). Hypoproteinaemia is also an independent risk factor for poor prognosis in CS (33, 34). In our study, we analyzed the effect of albumin infusion on the prognosis of patients with different albumin levels in two groups and found that levels at 24 and 48 h after admission correlated with 30-day mortality and that the level was lower and mortality higher, especially at 24 h. In the study, the SOFA score on the first day was high, the albumin level low, the central venous pressure (CVP) high, and the 30-day mortality low in the combined albumin group. After combined albumin resuscitation, the CVP was still high, but there was no significant difference in plasma albumin level between the two groups; even after PSM, the minimum albumin level on the second day was higher in the early combination group than in the crystalloid alone group. Moreover, 30-day mortality was significantly lower than that in the crystal fluid resuscitation-only group. Therefore, we used the E-value to assess whether unmeasured protective factors influence existing outcomes, indicating that early combined albumin resuscitation can reduce the 30-day mortality of CS patients. This study has several limitations. First, we failed to extract hypovolemic status and pulmonary oedema upon ICU admission. Although we sought to adjust confounding factors and minimize potential bias, the disadvantages of a retrospective study cannot be avoided. A rigorously designed randomized controlled study may be the only way to resolve the imbalance between the groups. Second, we deduced that the use of albumin might decrease mortality in this specific cohort. However, the adverse effects of albumin, such as aggravating pulmonary edema, should also be considered. Overall, the findings should be interpreted with caution, especially for patients with no shortage of volume or volume overload. Third, the missing albumin level and CVP value data were larger than 40% and we did not perform multiple imputations. However, the association between early albumin combination and 30-day mortality was further confirmed by PSM analysis in CS patients aged ≥60 with no albumin deficiency on day 1. Finally, although PSM may minimize possible confounders, it also significantly reduced the sample size of our study population, compared with the original data, the distribution of the matched dataset was smaller. Therefore, the results should be interpreted with caution. Further prospective research is needed to verify our findings.

CONCLUSIONS

Early resuscitation with combination albumin is associated with lower 30-day mortality in patients with CS aged ≥60, especially in patients with maximum SOFA ≥10, AMI, without Impella or IABP, and with or without furosemide and mechanical ventilation. In the future, more extensive randomized clinical trials are needed to confirm and verify this association.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research Ethics Committee of Shenzhen Second People’s Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

MW and Z-yZ were responsible for the study concept and design. Z-yZ and BW were responsible for collecting the data. Z-yZ was responsible for the statistical analysis. Y-yL and Z-yZ were responsible for drafting the manuscript. W-jiangP, Z-pZ, J-jH, Z-jJY, and J-jZ were responsible for literature and data. Z-yZ was responsible for the statistical analysis. Y-yL was responsible for data analysis. MW and BC was responsible for critical reading and Z-pZ, J-jH, Z-jY, and J-jZ were responsible for literature and Z-yZ was responsible for drafting the manuscript. W-jP, Z-pZ, J-jH, Z-jJY, and J-jZ were responsible for literature and Z-yZ was responsible for drafting the manuscript. W-jP, Z-pZ, J-jH, Z-jJY, and J-jZ were responsible for literature and Z-yZ was responsible for drafting the manuscript. W-jP, Z-pZ, J-jH, Z-jJY, and J-jZ were responsible for literature and Z-yZ was responsible for drafting the manuscript.

FUNDING

This work was supported by grants from the Sanming Project of Medicine in Shenzhen (SZSM20162011), Shenzhen Science and Technology Innovation Commission (JCYJ20190806163603504), and Shenzhen Second People’s Hospital Clinical Research Fund of Guangdong Province High-level Hospital Construction Project (20173357201815, 20193357003, and 20203357014).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.879812/full#supplementary-material

REFERENCES

1. Tewelde SZ, Liu SS, Winters ME. Cardiogenic shock. Cardiol Clin. (2018) 36:53–61. doi: 10.1016/j.ccl.2017.08.009

2. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. (2017) 136:e232–68. doi: 10.1161/CIR.0000000000000525
3. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. (1999) 341:625–34. doi:10.1056/NEJM199908263410901

4. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. (2019) 40:2671–83. doi:10.1093/eurheartj/ehz363

5. Cairoi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. (2014) 370:1412–21. doi:10.1056/NEJMoa1305727

6. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. Comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. (2004) 350:2247–56. doi:10.1056/NEJMoa0402322

7. Zhou S, Zeng Z, Wei H, Shu T, An S. Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database. Ann Intensive Care. (2021) 11:42. doi:10.1186/s13613-021-00830-8

8. Evans L, Rhodes A, Alhazimi W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. (2021) 47:1811–247. doi:10.1007/s00134-021-06506-y

9. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. (2012) 33:209–90. doi:10.1016/j.mam.2011.12.002

10. Evans TW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. (2002) 16 Suppl 5–6:11. doi:10.1046/j.1365-2046.1999.s.s.5.x

11. Belinskaia DA, Voronina PA, Jenkins RO, Goncharov A, et al. Human albumin is beneficial in conditions of septic shock: a systematic analysis. Crit Care. (2020) 24:360. doi:10.1186/s13054-020-03414-1

12. Levy B, Bastien O, Karim B, Cariou A, Chouihed T, Combes A, et al. Expert’s recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care. (2015) 5:52. doi:10.1186/s13613-015-0052-1

13. Zou, Wang, Peng, Zhou, Huang, Yang, Zhang, Luan, and Wu. Albumin Improves Survival of CS Patients: a Retrospective Study. Frontiers in Cardiovascular Medicine | www.frontiersin.org 10 May 2022 | Volume 9 | Article 879812

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zou, Wang, Peng, Zhou, Huang, Yang, Zhang, Luan, and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.